RALEIGH, N.C., July 22, 2024 /PRNewswire/ -- Caidya, a
leading global provider of clinical trial solutions, is pleased to
announce a transition in its executive leadership. Barbara Lopez Kunz, a distinguished member of
the Caidya Board of Directors, will assume the role of Chief
Executive Officer effective September 1,
2024. The current Chairman and CEO, Dr. Lingshi Tan, will
transition to Executive Chairman of the Board.
Barbara Lopez Kunz brings a
wealth of experience to the role, having served in various
leadership capacities across the healthcare and life sciences
sectors. With over 15 years of C-suite experience and a proven
track record in driving strategic partnerships and digital
transformation, Ms. Kunz is well-prepared to lead Caidya into its
next phase of growth and innovation.
Dr. Lingshi Tan expressed his enthusiasm for Ms. Kunz's
appointment, stating, "Barbara's leadership capabilities and
profound understanding of the global healthcare landscape have been
invaluable to our board. Her strategic vision and commitment to
innovation have already significantly impacted our business. I have
the utmost confidence in her ability to steer Caidya towards a
successful future. I am thrilled she has accepted this expanded
role and look forward to working closely with her."
In her new role, Ms. Kunz will focus on enhancing Caidya's
position as a global leader in clinical research, emphasizing the
importance of patient-centered trials and building personalized,
fit-for-purpose solutions. "I am honored to lead Caidya and build
on the strong foundation laid by Dr. Tan," said Ms. Kunz. "Caidya's
commitment to transforming the landscape of clinical research
resonates deeply with my professional philosophy.
I look forward to working closely with Dr. Tan and our talented
team to realize the strategic vision and continue our trajectory of
innovation and growth."
Barbara Lopez Kunz's career as an
executive leader is distinguished by her roles in catalyzing
winning strategies for multinational corporations and non-profit
organizations. She has held significant P&L responsibilities at
major companies including Thermo Fisher Scientific, DuPont, and ICI
(now AstraZeneca), as well as at non-profits like Battelle and DIA.
Her leadership style, characterized by a focus on clear strategic
direction, people development, and learning agility, has cultivated
strong teams and innovative practices throughout her career. Ms.
Kunz also brings decades of experience serving on public, private,
and non-profit boards, where she has been instrumental in
transformative strategies, enhancing shareholder value.
Reflecting on her appointment to the Caidya Board in
November 2022, Ms. Kunz expressed her
excitement to contribute her deep expertise in the life sciences
industry to enhance Caidya's innovativeness, build productive
partnerships, and develop talent as Caidya executes its global
growth strategy. Her dedication to creating a people- and
patient-first culture is well aligned with Caidya's corporate
values. As Caidya continues to evolve and expand its global impact,
Barbara's leadership will be instrumental in driving forward the
company's purpose of helping to bring life-changing therapies to
the global community through liberated clinical research.
For more information about Caidya and its services, please visit
www.caidya.com.
About Caidya
Caidya is a global, multi-therapeutic
clinical research organization (CRO) dedicated to advancing
healthcare innovation and accelerating the development of new
therapies. With full-service capabilities and a strategic footprint
in 23 countries and regions, our global network provides broad
access to diverse patient populations across the Americas,
Europe, and APAC. Caidya's
in-depth therapeutic and operational expertise helps partners
conduct studies with greater efficiency and confidence. Our
commitment to excellence and data-driven decision-making ensures
the highest quality standards across all phases of the drug
development process.
Caidya provides comprehensive clinical trial services from
regulatory strategy and submissions, clinical operations,
biometrics, and quality management, through post-approval
surveillance. Following the merger of dMed and Clinipace, Caidya
launched with a clear purpose to liberate clinical research and
bring life-changing therapies to our global community.
Media Contact:
Miron
Lila
VP, Head of Corporate Development and Investor Relations
Email: miron.lila@caidya.com
Logo -
https://mma.prnewswire.com/media/2309932/Caidya_logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/caidya-announces-leadership-transition-barbara-lopez-kunz-named-ceo-302202113.html